Search results for "temi"

showing 10 items of 3194 documents

Urinary levels of sirtuin-1 associated with disease activity in lupus nephritis.

2017

Identifying new markers of disease flares in lupus nephritis (LN) that facilitate patient stratification and prognosis is important. Therefore, the aim of the present study was to analyze whether urinary SIRT1 expression was altered in LN and whether SIRT1 values in urine could be valuable biomarker of disease activity. In a cohort study, urinary pellets from 40 patients diagnosed with systemic lupus erythematosus (SLE) were analyzed. Clinical measures of lupus activity were assessed. The expression of SIRT1 was quantified by quantitative PCR (qRT-PCR) and immunoblot, then compared between patients with active lupus nephritis, in remission and healthy controls. Association with lupus activi…

0301 basic medicineAdultMalemedicine.medical_specialtyUrinary systemLupus nephritisGene ExpressionDiseaseUrineKidneyGastroenterologySeverity of Illness IndexPathogenesisCohort Studies03 medical and health sciencesSirtuin 1Internal medicinemedicineHumansLupus Erythematosus Systemicskin and connective tissue diseasesAgedSystemic lupus erythematosusbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisLupus Nephritis030104 developmental biologyReal-time polymerase chain reactionBiomarker (medicine)FemalebusinessBiomarkersClinical science (London, England : 1979)
researchProduct

Secretion of autoimmune antibodies in the human subcutaneous adipose tissue

2018

The adipose tissue (AT) contributes to systemic and B cell intrinsic inflammation, reduced B cell responses and secretion of autoimmune antibodies. In this study we show that adipocytes in the human obese subcutaneous AT (SAT) secrete several pro-inflammatory cytokines and chemokines, which contribute to the establishment and maintenance of local and systemic inflammation, and consequent suboptimal immune responses in obese individuals, as we have previously shown. We also show that pro-inflammatory chemokines recruit immune cells expressing the corresponding receptors to the SAT, where they also contribute to local and systemic inflammation, secreting additional pro-inflammatory mediators.…

0301 basic medicineB CellsPhysiologylcsh:MedicineAutoimmunityPathology and Laboratory MedicineSystemic inflammationWhite Blood CellsAnimal CellsImmune PhysiologyPlasma cell differentiationAdipocytesMedicine and Health Scienceslcsh:ScienceImmune ResponseConnective Tissue CellsInnate Immune SystemMultidisciplinaryT CellsBody Fluids3. Good healthBloodmedicine.anatomical_structurePhysiological ParametersConnective TissueCytokinesChemokinesCellular TypesAnatomymedicine.symptomResearch ArticleLipolysisImmune CellsImmunologySubcutaneous FatInflammationBiology03 medical and health sciencesSigns and SymptomsImmune systemAntigenDiagnostic MedicinemedicineHumansObesityAntibody-Producing CellsB cellAutoantibodiesInflammationBlood CellsTumor Necrosis Factor-alphalcsh:RBody WeightAutoantibodyBiology and Life SciencesGerminal centerCell BiologyMolecular DevelopmentOxidative StressBiological Tissue030104 developmental biologyImmune SystemImmunologylcsh:QTranscription FactorsDevelopmental BiologyPLOS ONE
researchProduct

Intervention of Inflammatory Monocyte Activity Limits Dermal Fibrosis

2019

Monocytes and monocyte-derived cells are important players in the initiation, progression, and resolution of inflammatory skin reactions. As inflammation is a prerequisite for fibrosis development, we focused on the role of monocytes in cutaneous fibrosis, the clinical hallmark of patients suffering from systemic sclerosis. Investigating the function of monocytes in reactive oxygen species–induced dermal fibrosis, we observed that early monocyte depletion partially reduced disease severity. Low numbers of inflammatory Ly6Chigh monocytes, as well as inhibition of CCR2 and CCL2 in wild type animals by a specific L-RNA aptamer, mitigated disease parameters, indicating a pivotal role for CCR2+ …

0301 basic medicineCCR2Nerve growth factor IBReceptors CCR2InflammationDermatologyCCL2BiochemistryMonocytesSclerodermaMiceRandom Allocation03 medical and health sciences0302 clinical medicineReference ValuesFibrosisNuclear Receptor Subfamily 4 Group A Member 1medicineAnimalsHumansMolecular BiologyCells CulturedChemokine CCL2InflammationScleroderma Systemicbusiness.industryMonocyteInterferon-stimulated geneBiopsy NeedleCell Biologymedicine.diseaseImmunohistochemistryMice Inbred C57BLDisease Models Animal030104 developmental biologymedicine.anatomical_structureGene Expression Regulation030220 oncology & carcinogenesisImmunologymedicine.symptombusinessSignal TransductionJournal of Investigative Dermatology
researchProduct

Prevention of carcinogenesis and metastasis by Artemisinin-type drugs.

2018

Artemisia annua (sweet wormwood, qinhao) is an ancient Chinese herbal remedy for pyrexia. Nowadays, artemisinin (qinghaosu) and its derivatives belong to the standard therapies against malaria worldwide, and its discovery has led to the Nobel Prize in Physiology and Medicine to Youyou Tu in 2015. While most attention has been paid to the treatment of malaria, there is increasing evidence that Artemisinin-type drugs bear a considerable potential to treat and prevent cancer. Rather than reporting on therapy of cancer, this review gives a comprehensive and timely overview on the chemopreventive effects of artemisinin and its derivatives against carcinogenesis and metastasis formation, followin…

0301 basic medicineCancer ResearchCarcinogenesisArtemisia annuaCancer metastasisArtemisia annuaBioinformaticsmedicine.disease_causeMetastasis03 medical and health sciencesAntimalarials0302 clinical medicineNeoplasmsparasitic diseasesmedicineHumansArtemisininNeoplasm MetastasisToxicity profileClinical Trials as TopicbiologyMolecular Structurebusiness.industryCancermedicine.diseasebiology.organism_classificationArtemisinins030104 developmental biologyOncology030220 oncology & carcinogenesisCarcinogenesisbusinessMalariamedicine.drugPhytotherapyCancer letters
researchProduct

From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy.

2017

Artemisia annua L. is used throughout Asia and Africa as tea and press juice to treat malaria and related symptomes (fever, chills). Its active ingredient, artemisinin (ARS), has been developed as antimalarial drug and is used worldwide. Interestingly, the bioactivity is not restricted to malaria treatment. We and others found that ARS-type drugs also reveal anticancer in vitro and in vivo. In this review, we give a systematic overview of the literature published over the past two decades until the end of 2016. Like other natural products, ARS acts in a multi-specific manner against tumors. The cellular response of ARS and its derivatives (dihydroartemisinin, artesunate, artemether, arteeth…

0301 basic medicineCancer ResearchNecroptosismedicine.medical_treatmentArtemisia annuaDihydroartemisininPharmacologyArtemisia annua03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNeoplasmsmedicineHumansArtemetherArtemisininPI3K/AKT/mTOR pathwaybiologybiology.organism_classificationArtemisininsNeoplasm ProteinsGene Expression Regulation NeoplasticDrug repositioningOxidative Stress030104 developmental biologychemistryArtesunate030220 oncology & carcinogenesismedicine.drugSeminars in cancer biology
researchProduct

Repurposing of artemisinin-type drugs for the treatment of acute leukemia.

2020

Cancer treatment represents an unmet challenge due to the development of drug resistance and severe side effects of chemotherapy. Artemisinin (ARS)-type compounds exhibit excellent antimalarial effects with few side effects and drug-resistance. ARS and its derivatives were also reported to act against various tumor types in vitro and in vivo, including acute leukemia. Therefore, ARS-type compounds may be exquisitely suitable for repurposing in leukemia treatment. To provide comprehensive clues of ARS and its derivatives for acute leukemia treatment, their molecular mechanisms are discussed in this review. Five monomeric molecules and 72 dimers, trimers and hybrids based on the ARS scaffold …

0301 basic medicineCancer Researchmedicine.medical_treatmentAntineoplastic AgentsDrug resistancePharmacology03 medical and health sciencesAntimalarials0302 clinical medicineIn vivoNeoplasmsDrug DiscoverymedicineAnimalsHumansArtemisininRepurposingChemotherapyAcute leukemiabusiness.industryDrug Repositioningmedicine.diseaseIn vitroArtemisininsLeukemia030104 developmental biology030220 oncology & carcinogenesisbusinessmedicine.drugSeminars in cancer biology
researchProduct

Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients

2016

Spleen tyrosine kinase (SYK) is a protein kinase involved in cell proliferation and the regulation of inflammatory pathways. Due to the increasing evidence that kinase inhibitors have potential as specific anti-inflammatory drugs, we have investigated the potential for SYK inhibition as a therapeutic target in autoimmune diseases, particularly cutaneous lupus erythematosus (CLE). Skin samples of patients with different CLE subtypes and appropriate controls were analysed for the expression of SYK and SYK-associated pro-inflammatory mediators via gene expression analysis and immunohistochemistry. The functional role of SYK in keratinocytes was investigated in vitro, using LE-typical pro-infla…

0301 basic medicineCell typeSykchemical and pharmacologic phenomenaDermatologyenvironment and public healthBiochemistry03 medical and health sciencesImmune systemDownregulation and upregulationLupus Erythematosus CutaneousmedicineHumansSyk KinasePhosphorylationMolecular BiologyCells CulturedInnate immune systemSystemic lupus erythematosusKinasebusiness.industryhemic and immune systemsmedicine.diseaseenzymes and coenzymes (carbohydrates)030104 developmental biologyCase-Control StudiesImmunologyCytokinesPhosphorylationbiological phenomena cell phenomena and immunitybusinessExperimental Dermatology
researchProduct

FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines

2016

Intranodal immunization with antigen-encoding naked mRNA has proven to be an efficacious and safe approach to induce antitumor immunity. Thanks to its unique characteristics, mRNA can act not only as a source for antigen but also as an adjuvant for activation of the immune system. The search for additional adjuvants that can be combined with mRNA to further improve the potency of the immunization revealed Fms-like tyrosine kinase 3 (FLT3) ligand as a potent candidate. Systemic administration of the dendritic cell-activating FLT3 ligand prior to or along with mRNA immunization-enhanced priming and expansion of antigen-specific CD8(+) T cells in lymphoid organs, T-cell homing into melanoma tu…

0301 basic medicineChemistrymedicine.medical_treatmentPriming (immunology)chemical and pharmacologic phenomenaImmunotherapyDendritic cellbiochemical phenomena metabolism and nutrition03 medical and health sciences030104 developmental biologyImmune systemAntigenSystemic administrationmedicineCancer researchbacteriaAdjuvantCD8
researchProduct

Novel Immune Features of the Systemic Inflammation Associated with Primary Hypercholesterolemia: Changes in Cytokine/Chemokine Profile, Increased Pla…

2018

Primary hypercholesterolemia (PH) is associated with a low grade systemic inflammation that is likely the main driver of premature atherosclerosis. Accordingly, we characterized the immune cell behaviour in PH and its potential consequences. Whole blood from 22 PH patients and 21 age-matched controls was analysed by flow cytometry to determine the percentage of leukocyte immunophenotypes, activation, and platelet-leukocyte aggregates. Plasma markers were determined by Enzyme-Linked ImmunoSorbent Assay (ELISA). The adhesion of platelet-leukocyte aggregates to tumor necrosis factor-&alpha

0301 basic medicineChemokinemedicine.medical_treatmentlcsh:Medicinechemokines030204 cardiovascular system & hematologySystemic inflammationArticleendothelial dysfunction03 medical and health sciences0302 clinical medicineleukocyte activationResposta immunitàriaprimary hypercholesterolemiaplatelet activationMedicinePlateletPlatelet activationEndothelial dysfunctionSistema cardiovascularsystemic inflammationbiologybusiness.industryMonocytelcsh:REndoteli vascularGeneral Medicinemedicine.diseasecytokines030104 developmental biologyCytokinemedicine.anatomical_structureImmunologybiology.proteinTumor necrosis factor alphamedicine.symptombusinessJournal of clinical medicine
researchProduct

A rare association of chronic lymphocytic leukemia with c-ANCA-positive Wegener’s granulomatosis: a case report

2016

Background Wegener’s granulomatosis is a systemic vasculitis of the small- and medium-sized vessels, produced by the action of ANCA, which involves the respiratory tract, kidneys, and eyes, with a potential for lethal evolution in the first year after diagnosis. Its association with chronic lymphocytic leukemia is rarely described in the literature, and it may be difficult to diagnose and to treat this association. Case presentation We present the case of a 73-year-old Caucasian patient, a rare case in which Wegener’s granulomatosis is associated in a patient with chronic lymphocytic leukemia, who is admitted in the Infectious Disease Department for fever, diplopia, headache, purulent and h…

0301 basic medicineChemosisMalePathologymedicine.medical_specialtyChronic lymphocytic leukemiaMucous membrane of noseCase ReportAntibodies Antineutrophil Cytoplasmic03 medical and health sciences0302 clinical medicineBiopsymedicinec-ANCA positiveHumansAgedmedicine.diagnostic_testbusiness.industryGranulomatosis with PolyangiitisWegener’s granulomatosismedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-Cell030104 developmental biologyOncology030220 oncology & carcinogenesisChronic lymphocytic leukemiaSurgerymedicine.symptomGranulomatosis with polyangiitisVasculitisbusinessScleritisSystemic vasculitisWorld Journal of Surgical Oncology
researchProduct